BSX AXNX: Boston Scientific Announces Pricing of €2 Billion Notes Offering

By Patricia Miller


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Boston Scientific Corp (BSX stock) announces €2 billion notes offering, financing strategic AXNX acquisition and providing investment opportunities.

Boston Scientific Stock Science Boston Scientific company logo displayed on mobile phone.

What You Need To Know

Boston Scientific Corporation (NYSE: BSX), a global medical technology leader, has announced the pricing of €750 million aggregate principal amount of 3.375% notes due 2029 and €1.25 billion aggregate principal amount of 3.500% notes due 2032. These notes will be fully guaranteed by the Company and the offering is expected to close on February 27, 2024.

The net proceeds from the offering, along with borrowings and cash on hand, will be used to finance the acquisition of Axonics Inc (NASDAQ: AXNX) and to pay related fees and expenses. Additionally, the funds will be used to repay 3.450% senior notes due in March 2024 and for general corporate purposes.

Interested investors can obtain more information about the offering from the joint book-running managers: Barclays Bank PLC, Citigroup Global Markets Europe AG, and Société Générale.

Boston Scientific is committed to transforming lives through innovative medical technologies that improve patient health globally. They offer a broad range of solutions for complex diseases and conditions across various medical disciplines.

Sign up for Investing Intel Newsletter

Why This Is Important for Retail Investors

  1. Investment opportunity: The pricing of the notes offering presents a potential investment opportunity for retail investors who are looking to diversify their portfolios and participate in the medical technology sector.

  2. Guaranteed by the Company: The notes being offered are fully and unconditionally guaranteed by Boston Scientific Corporation, providing an added layer of security for retail investors.

  3. Funding a strategic acquisition: The net proceeds from the offering will be used to finance the acquisition of Axonics, Inc. This highlights the growth strategy of Boston Scientific and the potential positive impact on the company's future performance, which can be appealing to retail investors.

  4. Repayment of existing notes: A portion of the funds raised through the offering will be used to repay the company's existing senior notes. This demonstrates Boston Scientific's commitment to maintaining a strong financial position and fulfilling its debt obligations.

  5. Broad range of medical solutions: Boston Scientific's diverse portfolio of devices and therapies addresses various medical conditions and diseases, offering retail investors exposure to a company that operates across multiple healthcare sectors. This breadth of offerings may provide opportunities for long-term growth and stability.

How Can You Use This Information?

Here are some of the investing ideas that can be explored using this information:

Growth Investing

The funding of Boston Scientific's strategic acquisition of Axonics (AXNX stock) suggests growth potential for the company, making it an interesting prospect for growth-oriented investors.

Sector Rotation

The medical technology sector, represented by Boston Scientific (BSX), can be an attractive segment for sector rotation strategies as it offers potential growth and innovation opportunities.


Including BSX stock in an investment portfolio could potentially enhance diversification, especially for investors seeking exposure to the healthcare sector.

Event-Driven Strategy

The notes offering, along with the planned acquisition, represents a significant corporate event that event-driven strategy investors may explore for potential investment opportunities.

Income Investing

With the offering of guaranteed notes, income-seeking investors can consider Boston Scientific as a potential source of stable income through fixed interest payments.

Read What Others Are Saying

Reuters: Medical device maker Boston Scientific to buy Axonics for $3.7 billion

PR Newswire: Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes

Boston Scientific: Boston Scientific Announces Agreement to Acquire Axonics, Inc.

Sign up for Investing Intel Newsletter

What you should read next:

Popular ETFs

Some investors prefer to invest in stocks via an exchange-traded fund for ease and reduced risk. Some popular ETFs include the following:

  • Large-Caps: Vanguard Mega Cap ETF (MGC)

  • Mid-Caps: Vanguard Mid-Cap ETF (VO)

  • Small-Caps: Vanguard Small-Cap ETF (VB)

  • Growth: iShares Core S&P U.S. Growth ETF (IUSG)

  • Value: iShares Core S&P US Value ETF (IUSV)

  • Emerging Markets: Vanguard FTSE Emerging Markets ETF (VWO)

  • Developed Markets: Vanguard FTSE Developed Markets ETF (VEA)

  • Obesity and Heart Disease: Tema Cardiovascular and Metabolic ETF (HRTS)

Explore more on these topics:



This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter